160 related articles for article (PubMed ID: 25759825)
1. GK-1 improves the immune response induced by bone marrow dendritic cells loaded with MAGE-AX in mice with melanoma.
Piñón-Zárate G; Herrera-Enríquez MÁ; Hernández-Téllez B; Jarquín-Yáñez K; Castell-Rodríguez AE
J Immunol Res; 2014; 2014():158980. PubMed ID: 25759825
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
3. Lentiviral vector-mediated autonomous differentiation of mouse bone marrow cells into immunologically potent dendritic cell vaccines.
Koya RC; Kimura T; Ribas A; Rozengurt N; Lawson GW; Faure-Kumar E; Wang HJ; Herschman H; Kasahara N; Stripecke R
Mol Ther; 2007 May; 15(5):971-80. PubMed ID: 17375074
[TBL] [Abstract][Full Text] [Related]
4. Activated natural killer cell-mediated immunity is required for the inhibition of tumor metastasis by dendritic cell vaccination.
Kim A; Noh YW; Kim KD; Jang YS; Choe YK; Lim JS
Exp Mol Med; 2004 Oct; 36(5):428-43. PubMed ID: 15557815
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cells stimulated with outer membrane protein A (OmpA) of Salmonella typhimurium generate effective anti-tumor immunity.
Jang MJ; Kim JE; Chung YH; Lee WB; Shin YK; Lee JS; Kim D; Park YM
Vaccine; 2011 Mar; 29(13):2400-10. PubMed ID: 21276440
[TBL] [Abstract][Full Text] [Related]
6. Melanoma-infiltrating dendritic cells induce protective antitumor responses mediated by T cells.
Preynat-Seauve O; Contassot E; Schuler P; French LE; Huard B
Melanoma Res; 2007 Jun; 17(3):169-76. PubMed ID: 17505262
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
8. Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients.
Davis ID; Chen Q; Morris L; Quirk J; Stanley M; Tavarnesi ML; Parente P; Cavicchiolo T; Hopkins W; Jackson H; Dimopoulos N; Tai TY; MacGregor D; Browning J; Svobodova S; Caron D; Maraskovsky E; Old LJ; Chen W; Cebon J
J Immunother; 2006; 29(5):499-511. PubMed ID: 16971806
[TBL] [Abstract][Full Text] [Related]
9. Antitumor immune response of dendritic cells (DCs) expressing tumor-associated antigens derived from induced pluripotent stem cells: in comparison to bone marrow-derived DCs.
Iwamoto H; Ojima T; Hayata K; Katsuda M; Miyazawa M; Iida T; Nakamura M; Nakamori M; Iwahashi M; Yamaue H
Int J Cancer; 2014 Jan; 134(2):332-41. PubMed ID: 23824921
[TBL] [Abstract][Full Text] [Related]
10. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
[TBL] [Abstract][Full Text] [Related]
11. Augmentation of antitumor immune responses after adoptive transfer of bone marrow derived from donors immunized with tumor lysate-pulsed dendritic cells.
Asavaroengchai W; Kotera Y; Koike N; Pilon-Thomas S; Mulé JJ
Biol Blood Marrow Transplant; 2004 Aug; 10(8):524-33. PubMed ID: 15282530
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of melanoma growth after treatment with dendritic cells in a Tyr-SV40E murine model requires CD4+ T cells but not CD8+ T cells.
Milling SW; Sai T; Silvers WK; Mintz B
Melanoma Res; 2004 Dec; 14(6):555-62. PubMed ID: 15577330
[TBL] [Abstract][Full Text] [Related]
13. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration.
Eggert AA; Schreurs MW; Boerman OC; Oyen WJ; de Boer AJ; Punt CJ; Figdor CG; Adema GJ
Cancer Res; 1999 Jul; 59(14):3340-5. PubMed ID: 10416590
[TBL] [Abstract][Full Text] [Related]
14. The role of the e3 ligase cbl-B in murine dendritic cells.
Wallner S; Lutz-Nicoladoni C; Tripp CH; Gastl G; Baier G; Penninger JM; Stoitzner P; Wolf D
PLoS One; 2013; 8(6):e65178. PubMed ID: 23762309
[TBL] [Abstract][Full Text] [Related]
15. Type I-polarized BRAF-pulsed dendritic cells induce antigen-specific CD8+ T cells that impact BRAF-mutant murine melanoma.
Cintolo JA; Datta J; Xu S; Gupta M; Somasundaram R; Czerniecki BJ
Melanoma Res; 2016 Feb; 26(1):1-11. PubMed ID: 26451873
[TBL] [Abstract][Full Text] [Related]
16. Engineering of highly immunogenic long-lived DC vaccines by antiapoptotic protein gene transfer to enhance cancer vaccine potency.
Yoshikawa T; Niwa T; Mizuguchi H; Okada N; Nakagawa S
Gene Ther; 2008 Oct; 15(19):1321-9. PubMed ID: 18480845
[TBL] [Abstract][Full Text] [Related]
17. Vitamin C treatment of mouse bone marrow-derived dendritic cells enhanced CD8(+) memory T cell production capacity of these cells in vivo.
Jeong YJ; Kim JH; Hong JM; Kang JS; Kim HR; Lee WJ; Hwang YI
Immunobiology; 2014 Jul; 219(7):554-64. PubMed ID: 24698552
[TBL] [Abstract][Full Text] [Related]
18. The helminth-derived peptide GK-1 induces an anti-tumoral CD8 T cell response associated with downregulation of the PD-1/PD-L1 pathway.
Rodríguez-Rodríguez N; Madera-Salcedo IK; Bugarin-Estrada E; Sánchez-Miranda E; Torres-García D; Cervantes-Torres J; Fragoso G; Rosetti F; Crispín JC; Sciutto E
Clin Immunol; 2020 Mar; 212():108240. PubMed ID: 31299381
[TBL] [Abstract][Full Text] [Related]
19. Tissue localization of tumor antigen-loaded mouse dendritic cells applied as an anti-tumor vaccine and their influence on immune response.
Rossowska J; Pajtasz-Piasecka E; Szyda A; Zietara N; Duś D
Folia Histochem Cytobiol; 2007; 45(4):349-55. PubMed ID: 18165174
[TBL] [Abstract][Full Text] [Related]
20. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
